Merck (MRK) debt: $49B
Merck had $49B of long-term debt on Dec 31, 2025, including the part due within a year, up 32.7% from $37B a year earlier.
From Merck's filings with the SEC · Read the filing · MRK stock page
Merck debt by year
#27 of 2,129 US companies by debt · See the full ranking
| Year ended | Debt | Change |
|---|---|---|
| Dec 31, 2025 | $49B | +33% |
| Dec 31, 2024 | $37B | +6% |
| Dec 31, 2023 | $35B | +15% |
| Dec 31, 2022 | $30.4B | -8% |
| Dec 31, 2021 | $33B | – |
Debt of similar companies
Companies in the same industry as Merck, by SEC industry code, with the closest debt. Each name opens the same page for that company.
| Company | Debt, latest year | Year ended |
|---|---|---|
| Pfizer | $64.6B | Dec 31, 2025 |
| AbbVie | $64.5B | Dec 31, 2025 |
| Merck | $49B | Dec 31, 2025 |
| Bristol Myers Squibb | $44.8B | Dec 31, 2025 |
| Johnson & Johnson | $41.4B | Dec 28, 2025 |
| Eli Lilly | $40.9B | Dec 31, 2025 |
| Bausch Health Companies | $20.8B | Dec 31, 2025 |
Questions and answers
What is Merck's debt?
Merck had $49B of long-term debt on Dec 31, 2025, including the part due within a year, up 32.7% from $37B a year earlier.
Numbers as reported in Merck's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology